Document Detail

Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension.
MedLine Citation:
PMID:  6119558     Owner:  NLM     Status:  MEDLINE    
In all subjects of the Australian therapeutic trial in mild hypertension, mean pressures for the two screening visits were within the range 95-109 mm Hg for diastolic blood-pressure phase V(DBP) and less than 200 mm Hg for systolic blood-pressure (SBP). In the 1943 control (placebo) subjects mean blood-pressures fell from 158/102 mm Hg at the first screening visit to 144/91 mm Hg 3 years later. At that time pressures remained within the mild hypertension range in 32%, ahd risen above it in 12%, and had fallen below in 48%. Trial end-points (ischaemic heart disease or cerebrovascular accident) occurred in 8%. The outcome was related to the level of initial pressure but not to other characteristics measured at entry. The mean initial pressures of 22 subjects who experienced a cerebrovascular event were higher than those of a matched group with no hypertensive complications, but the 88 subjects who experienced ischaemic-heart-disease events had initial pressures similar to those in a matched control group. The trial end-point rate was related to the average DBP of subjects throughout the trial in those with average DBP greater than or equal to 95 mm Hg, and at those levels subjects on active treatment had a higher incidence than subjects of the placebo group with the same DBP level. For those with average DBP below 95 mm Hg the incidence of trial end-points was not related to blood-pressure level or treatment. 16% of placebo subjects in this mild hypertensive population had a mean DBP of less than 95 mm Hg at the first three visits. If this were taken as an indication to withhold drug treatment, 3 years later one-quarter of them (4% of all subjects) would be found to be hypertensive or to have experienced a trial end-point, and thus inappropriately untreated, while the other 12% would have pressures below 95 mm Hg and have had no trial end-point.
Related Documents :
2097358 - Effect of intravenous infusion of verapamil in patients of severe hypertension.
2894168 - Efficacy and safety of rilmenidine for arterial hypertension.
17855798 - Estimating the proportion of young adults on antihypertensive treatment that have been ...
23162388 - Anesthesia for thoracic surgery: a survey of middle eastern practice.
21087408 - Toward more useful pressure-controlled discography: in vitro evaluation of injection sp...
1545558 - Mechanical enhancement and myocardial oxygen saving by synchronized dynamic left ventri...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Lancet     Volume:  1     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1982 Jan 
Date Detail:
Created Date:  1982-03-22     Completed Date:  1982-03-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  185-91     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure*
Blood Pressure Determination
Cerebrovascular Disorders / etiology
Clinical Trials as Topic
Coronary Disease / etiology
Double-Blind Method
Hypertension* / drug therapy,  physiopathology
Middle Aged
Random Allocation
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is recurrence inevitable after gallstone dissolution by bile-acid treatment?
Next Document:  Serum salicylate concentrations in Reye's disease. A study of 130 biopsy-proven cases.